ASP Isotopes Stock Price, News & Analysis

ASP Isotopes (NASDAQ:ASPI) and its subsidiary Quantum Leap Energy (QLE) have entered into a strategic MOU with Fermi America to develop advanced nuclear fuel facilities at the planned 11GW HyperGrid Campus in Texas. The partnership includes two key components: a joint venture between QLE and Fermi America for HALEU nuclear fuel production, and a separate facility for ASPI to produce stable isotopes and advanced materials.

The HyperGrid Campus, co-founded by former U.S. Energy Secretary Rick Perry, will be located near the DOE's Pantex Plant in Carson County. The project aims to become the world's largest hybrid energy and data infrastructure campus, with construction starting in 2027 and the first reactor operational by 2032.

QLE has received significant interest from potential customers, with projected HALEU demand of over $37 billion through 2037. This Texas facility would be QLE's second HALEU production site, complementing their planned South African facility supporting TerraPower's Natrium project.

ASP Isotopes (NASDAQ:ASPI) has received approval for a dual listing on the Johannesburg Stock Exchange (JSE), expected to commence on August 27, 2025. The company will maintain its primary Nasdaq listing while trading on JSE's Main Board under the code "ISO".

This announcement follows ASPI's May 2025 plan to acquire Renergen Limited through a scheme arrangement where Renergen shareholders will receive 0.09196 ASPI shares per Renergen share. The acquisition, supported by 99.8% of Renergen shareholders, aims to create a global critical materials leader and is expected to close in Q3 2025.

The combined entity targets over $300 million in EBITDA by 2030, driven by isotopes, helium, and LNG sales. The transaction is projected to be highly accretive to ASPI's revenue, EBITDA, and earnings per share in 2026.

ASP Isotopes (NASDAQ:ASPI) has invested $5 million in a Series Seed funding round for IsoBio, Inc., a U.S.-based radiotherapeutic development company. IsoBio is developing antibody-isotope conjugates (AICsTM) for cancer treatment, combining monoclonal antibodies with novel isotopes including Lutetium-177, Actinium-225, and Terbium-161.

The company is led by Dr. Bruce Turner, a radiation oncologist and biotech executive, and will establish operations in Seattle, WA and Gladwyne, PA. The strategic partnership aims to leverage ASPI's technology and manufacturing capabilities through its subsidiary PET Labs to address critical isotope supply chain challenges in radiotherapy development.

ASP Isotopes (NASDAQ:ASPI) has received approval from the Competition Commission of South Africa for its proposed acquisition of JSE-listed Renergen Limited. The approval, granted on July 23, 2025, comes with certain acceptable conditions.

The transaction, expected to close in Q3 2025, aims to create a global leader in critical materials production, including helium, fluorinated products, and isotopically enriched gases. The merger is projected to be highly accretive to ASPI's financials starting 2026, with the combined entity targeting $300 million in EBITDA by 2030.

The deal remains subject to additional regulatory approvals and third-party consents, with a deadline of September 30, 2025, unless extended.

ASP Isotopes (NASDAQ:ASPI) has announced the pricing of an underwritten registered direct offering of 7.5 million shares of common stock at $8.00 per share to a single fundamental institutional investor. The offering is expected to generate gross proceeds of approximately $60 million.

The offering, expected to close around July 25, 2025, will be managed jointly by Cantor and Canaccord Genuity as book-running managers, with Ocean Wall Limited acting as financial advisor. The company plans to use the net proceeds for general corporate purposes, including working capital, operating expenses, and capital expenditures.

ASP Isotopes (NASDAQ:ASPI) reported significant progress at its three isotope enrichment facilities in South Africa. The company has achieved major milestones in Silicon-28 production, reaching 99% enrichment with increased annual capacity of >80kg (vs previous 50kg guidance), requiring a $4M investment. The Ytterbium-176 facility commenced production in April 2025, achieving 92.4% enrichment with plans to reach 99.75% in a two-step process.

The company is transitioning its Ytterbium-176 production to semi-continuous processing in August 2025, targeting 1kg annual production. Additionally, ASPI received permits for Nickel-64, Gadolinium-160, and Zinc-68 enrichment, while its Carbon facility is now producing Carbon-12 at 99.99% purity. The company maintains plans to spin out Quantum Leap Enrichment in October 2025 and expects to close the Renergen acquisition in Q3 2025.

ASP Isotopes (NASDAQ:ASPI) announced that Renergen Limited shareholders have overwhelmingly approved (99.80% in favor) the proposed acquisition through a scheme of arrangement. The transaction, expected to close in Q3 2025, is subject to regulatory approvals and other conditions by September 30, 2025.

The merger aims to create a global leader in critical materials production, combining ASP's isotope capabilities with Renergen's helium and LNG operations. The combined entity projects over $300 million in EBITDA by 2030, driven by isotopes, helium, and LNG sales. The deal is expected to be highly accretive to ASPI's revenue, EBITDA, and earnings starting from 2026.

ASP Isotopes (NASDAQ: ASPI) has appointed Dr. Ryno Pretorius as CEO of its subsidiary Quantum Leap Energy LLC (QLE), which focuses on developing advanced nuclear fuels like HALEU and Lithium-6. Dr. Pretorius brings extensive experience in chemical engineering and nuclear fuel technology, having previously worked at Necsa and as CEO of Free Radical Process Design. QLE plans to spin out in H2 2025 and has secured financing from TerraPower for a HALEU production facility in South Africa. The company's proprietary Quantum Enrichment process is expected to produce HALEU at competitive costs, supporting the growth of advanced nuclear reactors. Their first facility for Ytterbium-176 production completed commissioning in H1 2025. As part of his appointment, Dr. Pretorius received an inducement grant of 30,000 shares vesting over four years.

ASP Isotopes (NASDAQ: ASPI) has announced an Investor Access Event in South Africa from June 16-18, 2025, with a potential extension to visit the Renergen Virginia Gas Project on June 19. The event offers investors facility tours, scientific sessions, and direct interaction with management. The company, which successfully hosted over 60 investors in 2024 and 27 investors from 3 continents in January 2025, requires attendees to submit passport copies by June 7 for security clearance. As of April 2025, ASPI is commercially enriching Carbon-14 and Silicon-28, with their Ytterbium-176 plant producing commercial samples. Participants will visit three facilities, PET Labs radioisotope production centre, and Pelindaba, the South African Nuclear Energy Corporation center.